32000
document
[ Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients ] . OBJECTIVE To compare the long-term effect and safety of tacrolimus ( FK506 ) and cyclosporine ( CsA ) in kidney transplant ( KT ) recipients carrying hepatitis B Virus ( HBV ) . METHODS A total of 109 patients with HBV were randomized into FK506 group ( 52 cases ) and CsA group ( 57 cases ) after KT , and a 2-year-long follow-up of the patients was conducted to record the patient and graft survival , incidence of acute graft rejection and postoperative liver function . RESULTS The 2-year patient/graft survival was 86.0 % /73.7 % and 94.2 % /90.3 % in CsA and FK506 groups , respectively ( P < 0.05 ) , with incidence of acute rejection of 10.5 % and 9.6 % ( P > 0.05 ) , and rate of abnormal liver function of 26.3 % and 15.4 % ( P < 0.05 ) , respectively . Eight patients ( 14.4 % ) in CsA group required a drug conversion but none in FK506 group . The drug conversion resulted in significant reduction of ALT/AST level from 255.13+/-31.38/201.88+/-21.25 U/L to 31.25+/-11.50/25.13+/-9.68 U/L ( P < 0.01 ) . CONCLUSION For HBV-carrying renal transplant recipients , FK506 as the primary choice of immunosuppressant can be more effective and safer than CsA .
32001
Intervention_Pharmacological
tacrolimus
32002
Intervention_Pharmacological
cyclosporine A
32003
Intervention_Pharmacological
tacrolimus ( FK506 )
32004
Intervention_Pharmacological
cyclosporine ( CsA )
32005
Intervention_Pharmacological
FK506
32006
Intervention_Pharmacological
CsA
32007
Intervention_Pharmacological
FK506
32008
Outcome_Mortality
patient and graft survival
32009
Outcome_Physical
incidence of acute graft rejection
32010
Outcome_Physical
postoperative liver function
32011
Outcome_Mortality
2-year patient/graft survival
32012
Outcome_Adverse-effects
acute rejection
32013
Outcome_Physical
abnormal liver function
32014
Outcome_Physical
ALT/AST level
32015
Participant_Condition
HBV-carrying renal transplant recipients
32016
Participant_Condition
kidney transplant ( KT ) recipients carrying hepatitis B Virus ( HBV ) .
32017
Participant_Sample-size
109 patients
32018
Participant_Condition
HBV-carrying renal transplant recipients